- Home
- FIHL vs DYN Comparison
FIHL vs DYN Comparison
Compare FIHL & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIHL
- DYN
- Stock Information
- Founded
- FIHL 2014
- DYN 1984
- Country
- FIHL Bermuda
- DYN United States
- Employees
- FIHL N/A
- DYN N/A
- Industry
- FIHL
- DYN Medicinal Chemicals and Botanical Products
- Sector
- FIHL
- DYN Health Care
- Exchange
- FIHL Nasdaq
- DYN Nasdaq
- Market Cap
- FIHL 1.8B
- DYN 1.4B
- IPO Year
- FIHL 2023
- DYN 2020
- Fundamental
- Price
- FIHL $15.94
- DYN $10.32
- Analyst Decision
- FIHL Hold
- DYN Strong Buy
- Analyst Count
- FIHL 7
- DYN 14
- Target Price
- FIHL $20.14
- DYN $44.57
- AVG Volume (30 Days)
- FIHL 786.5K
- DYN 2.5M
- Earning Date
- FIHL 08-13-2025
- DYN 08-11-2025
- Dividend Yield
- FIHL 2.51%
- DYN N/A
- EPS Growth
- FIHL N/A
- DYN N/A
- EPS
- FIHL N/A
- DYN N/A
- Revenue
- FIHL $2,558,400,000.00
- DYN N/A
- Revenue This Year
- FIHL $24.21
- DYN N/A
- Revenue Next Year
- FIHL $5.09
- DYN N/A
- P/E Ratio
- FIHL N/A
- DYN N/A
- Revenue Growth
- FIHL 23.93
- DYN N/A
- 52 Week Low
- FIHL $14.17
- DYN $6.36
- 52 Week High
- FIHL $21.32
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- FIHL 38.01
- DYN 34.25
- Support Level
- FIHL $15.95
- DYN $10.56
- Resistance Level
- FIHL $16.99
- DYN $15.23
- Average True Range (ATR)
- FIHL 0.48
- DYN 1.01
- MACD
- FIHL -0.18
- DYN -0.47
- Stochastic Oscillator
- FIHL 1.48
- DYN 4.10
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.